The Pediatric Hematology/Oncology Division of Emory University is the only Pediatric Cancer Center within a radius of 180 miles. This center offers multimodal therapy to children with malignant disorders. The Division cares for the children in the Atlanta area (population 2.5 million), the State of Georgia and other neighboring states including Alabama, North Carolina, South Carolina, and Florida. Emory University is one of the largest contributor of patients to the Pediatric Oncology Group (POG) and has been so for the last 10 years earlier in SWOG. Emory University is one of the largest single contributor of patients to POG Phase I and Phase II studies. It is also a member of the special Phase I study group. Several research projects are currently underway. These include the investigation of Interleukin-2 (IL-2) in the treatment of children with acute leukemia and solid tumors. Along with this Phase I study, we are also investigating the activation of natural killer cells (NK cells) and LAK (lymphocyte activated killer cells) in children with acute leukemia and solid tumors. We have modified the IL-2 protocol, through better choice of patients, and altering the rate of infusion of IL-2, so that this agent can be safely given on an outpatient basis - a major accomplishment. Our Division is very active in biological response modifiers and a Phase I protocol is being developed to evaluate the use of interferon alpha in combination with IL-2. In addition we are investigating the use of retinoic acid and homoharringtonine in acute myelogenous leukemia. We are also investigating the use of myeloperoxidase messanger RNA probes in the diagnosis of unclassified leukemia. These probes will be used in the diagnosis of infant leukemias in the new infant leukemia protocol. Our Division is very actively involved in the investigation of the role of growth factors in the development of acute lymphocytic leukemia (ALL). We have demonstrated that low molecular weight B-cell growth factor is a potent stimulator of ALL cells. We are investigating a new autocrine growth factor in ALL. We have also demonstrated that IL-6 inhibits the growth of ALL cells. All of these investigation may be of potential therapeutic value in the diagnosis and treatment of ALL.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA020549-15
Application #
3556532
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1978-01-01
Project End
1995-12-31
Budget Start
1991-04-25
Budget End
1991-12-31
Support Year
15
Fiscal Year
1991
Total Cost
Indirect Cost
Name
Emory University
Department
Type
Schools of Medicine
DUNS #
042250712
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Wacker, Pierre; Land, Vita J; Camitta, Bruce M et al. (2007) Allergic reactions to E. coli L-asparaginase do not affect outcome in childhood B-precursor acute lymphoblastic leukemia: a Children's Oncology Group Study. J Pediatr Hematol Oncol 29:627-32
Ravindranath, Y; Chang, M; Steuber, C P et al. (2005) Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000. Leukemia 19:2101-16
Adamkiewicz, T V; Mehta, P S; Boyer, M W et al. (2004) Transplantation of unrelated placental blood cells in children with high-risk sickle cell disease. Bone Marrow Transplant 34:405-11
Seitzman, Robin L; Glover, Dorie A; Meadows, Anna T et al. (2004) Self-concept in adult survivors of childhood acute lymphoblastic leukemia: a cooperative Children's Cancer Group and National Institutes of Health study. Pediatr Blood Cancer 42:230-40
Shamberger, Robert C; LaQuaglia, Michael P; Gebhardt, Mark C et al. (2003) Ewing sarcoma/primitive neuroectodermal tumor of the chest wall: impact of initial versus delayed resection on tumor margins, survival, and use of radiation therapy. Ann Surg 238:563-7; discussion 567-8
Goorin, Allen M; Schwartzentruber, Douglas J; Devidas, Meenakshi et al. (2003) Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol 21:1574-80
Laver, Joseph H; Mahmoud, Hazem; Pick, Terry E et al. (2002) Results of a randomized phase III trial in children and adolescents with advanced stage diffuse large cell non-Hodgkin's lymphoma: a Pediatric Oncology Group study. Leuk Lymphoma 43:105-9
Bell, B A; Chang, M N; Weinstein, H J (2001) A phase II study of Homoharringtonine for the treatment of children with refractory or recurrent acute myelogenous leukemia: a pediatric oncology group study. Med Pediatr Oncol 37:103-7
Lauer, S J; Shuster, J J; Mahoney Jr, D H et al. (2001) A comparison of early intensive methotrexate/mercaptopurine with early intensive alternating combination chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group phase III randomized trial. Leukemia 15:1038-45
Saylors 3rd, R L; Stine, K C; Sullivan, J et al. (2001) Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol 19:3463-9

Showing the most recent 10 out of 67 publications